Needham & Company Gives Buy Rating to Solta Medical (SLTM)

By admin | 6 years ago

Solta Medical (NASDAQ: SLTM)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company in a report released on Wednesday.

Shares of Solta Medical traded down 4.98% during mid-day trading on Wednesday, hitting $3.05. Solta Medical has a 52 week low of $1.15 and a 52 week high of $3.69. The company’s market cap is $187.7 million.

SLTM has been the subject of a number of other recent research reports. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Solta Medical in a research note to investors on Wednesday. Separately, analysts at Raymond James (NYSE: RJF) initiated coverage on shares of Solta Medical in a research note to investors on Wednesday, April 25th. They set an “outperform” rating on the stock. Finally, analysts at Morgan Keegan upgraded shares of Solta Medical from a “market perform” rating to an “outperform” rating in a research note to investors on Monday, March 12nd. They now have a $3.75 price target on the stock, up previously from $3.50.

Solta Medical, Inc. designs, develops, manufactures and markets energy-based medical device systems for aesthetic applications.

About the author